Stocks to Keep an Eye on Today: A Mixed Bag of Builders, Energy and Pharma

It’s a fairly ordinary trading day, but the market’s not without its quirks. Investors are scanning a handful of names that could tip the scales, each coming from a different corner of the economy.

First up, Vascon Engineers (VASCONEQ). The Hyderabad‑based infrastructure player has been nudging its earnings outlook after landing a few road‑work contracts. While the numbers aren’t earth‑shattering, the steady cash flow might just make the stock a modest pick for risk‑averse buyers.

Then there’s Puravankara (PURVANKARA). The real‑estate developer is riding a brief lull in home‑loan rates, which has sparked a tiny uptick in its sales pipeline. Analysts are a bit split – some see a bounce‑back, others think the hype may fizzle once rates normalise.

Afcons Infrastructure (AFCONSINF) is another name on the watch‑list. The construction giant is reportedly gearing up for a mega‑port project in the west coast. If the contract materialises, it could pump up the top line, but the firm also faces execution risks that keep investors cautious.

Switching to the paper space, JK Paper (JKPAPER) posted a slightly better‑than‑expected quarter, thanks to a modest rise in pulp prices. Still, the sector’s overall demand is soft, so the rally might be short‑lived unless new export orders arrive.

On the energy front, GE Vernova (GEVERNO) – the newly spun‑off renewable arm of General Electric – is under the microscope. With wind‑farm orders picking up in Europe, the stock could benefit, yet the transition from a legacy business model brings a fair amount of uncertainty.

DOMS (DOMS) – the Indian nutraceutical firm – has been teasing a new line of health‑boosting supplements. Early market response looks promising, though the product rollout is still in its infancy, making the stock a bit of a gamble.

GNFC (GNFC), a stalwart in fertilizers and chemicals, reported a decent cash‑flow surprise. The company’s diversification into specialty chemicals could be a bright spot, but commodity price volatility remains a lingering concern.

Lastly, Goldline Pharmaceutical (GOLDLINE) is trying to shake off a recent dip by highlighting a pipeline of generic drugs that could capture market share once approvals come through. The upside potential is there, albeit wrapped in regulatory risk.

All told, today’s market could swing on any of these narratives. Keep an eye on earnings releases, policy cues and global commodity trends – they’ll likely decide which of these stocks earn a few extra points, and which stay flat.